Table 2 The proportion of cases (%) for different clinical and histological variables, according to EZH2 protein expression (A) and Ki-67 protein expression (B)

From: Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

(A)

 

EZH2 protein expression

 

Variable

Index 0–1, n =124

Index 2–4, n =87

Index 6–9, n =29

P -value *

Sex (n=240, female, %)

55.6

54.0

44.8

NS

Age (n=240, mean, years)

62.2

61.6

63.2

NS

Tumour localisation (n=240, proximal colon, %)

52.4

58.6

55.2

NS

Tumour stage (n=240, T3 and T4, %)

93.6

97.4

93.1

NS

Histological typea (n=232, adenocarcinoma, %)

93.4

81.9

92.9

0.028

Histological grade (n=235, poorly differentiated, %)

18.7

19.0

17.9

NS

TNM stage (n=240, stage III, %)

41.4

34.5

27.6

0.14**

Ki-67 (n=230, >40% tumour cells positive, %)

34.7

56.6

96.6

<0.001

Randomisation group (n=240, adjuvant chemotherapy, %)

47.6

55.2

51.7

NS

(B)

 

Ki-67 protein expression

 

Variable

<40%, n =134

⩾40 %, n =129

P-value *

 

Sex (n=263, female, %)

52.2

54.3

NS

 

Age (n=263, mean, years)

61.6

61.6

NS

 

Tumour localisation (n=263, proximal colon, %)

56.0

56.6

NS

 

Tumour stage (n=263, T3 and T4, %)

93.3

96.9

NS

 

Histological typea (n=256, adenocarcinoma, %)

91.6

87.2

NS

 

Histological grade (n=257, poorly differentiated, %)

21.1

16.9

NS

 

TNM stage (n=263, stage III, %)

42.5

31.8

0.07

 

EZH2 protein expression (=230, index 4–9, %)

6.1

29.1

<0.0001

 

Randomisation group (n=263, adjuvant chemotherapy, %)

51.5

51.9

NS

 
  1. Abbreviations: EZH2=enhancer of zeste homologue 2; NS=not significant; TNM=tumour–node–metastasis.
  2. Analyses include patients with colon cancer in TNM stages II and III.
  3. *P-values from chi-square statistics. NS: P>0.10.
  4. **P for trend.
  5. aOther histological types include mucinous adenocarcinoma and signet-ring cell carcinoma.
Back to article page